<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2341-4545</journal-id>
<journal-title><![CDATA[GE-Portuguese Journal of Gastroenterology]]></journal-title>
<abbrev-journal-title><![CDATA[GE Port J Gastroenterol]]></abbrev-journal-title>
<issn>2341-4545</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Gastrenterologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2341-45452021000600410</article-id>
<article-id pub-id-type="doi">10.1159/000511644</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Vedolizumab-Induced Liver Injury]]></article-title>
<article-title xml:lang="pt"><![CDATA[Hepatotoxicidade induzida pelo Vedolizumab]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saraiva]]></surname>
<given-names><![CDATA[Miguel Mascarenhas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[Tiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[Emanuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[Joanne Lopes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[Hélder]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Macedo]]></surname>
<given-names><![CDATA[Guilherme]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar Universitário de São João Gastroenterology Department ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Hospitalar de São João Pathology Department ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,University of Porto Faculty of Medicine ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>28</volume>
<numero>6</numero>
<fpage>410</fpage>
<lpage>415</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2341-45452021000600410&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2341-45452021000600410&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2341-45452021000600410&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Drug-induced liver injury is an important cause of acute liver injury. Immunomodulatory therapies, such as vedolizumab (VDZ), are being increasingly used for the treatment of several diseases, most importantly inflammatory bowel disease. Several studies have demonstrated the safety of this substance. To date, only one post-marketing study has reported a case of hepatotoxicity attributable to VDZ. The authors present the case of a 41-year-old woman followed at the gastroenterology outpatient clinic for ulcerative colitis (UC) and autoimmune hepatitis (AIH). This patient was being treated with low-dose glucocorticoids for AIH (prednisolone 10 mg), with adequate disease control. Additionally, she was being treated with oral salicylates (mesalamine 3 g/day) and oral budesonide (9 mg/day) for her UC. For uncontrolled UC, she was started on VDZ. Two weeks after the first infusion of VDZ, the patient developed a clinical and analytical phenotype compatible with acute hepatitis. Diagnostic workup for causes of hepatocellular liver injury retrieved no results. A liver biopsy corroborated the diagnosis of toxic hepatitis overlapping chronic liver disease. VDZ was withdrawn and the patient experienced complete recovery of liver tests over the following weeks. In this case report, we present the first post-marketing case of hepatocellular liver injury in probable relation to VDZ.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: A hepatotoxicidade induzida por fármacos é uma causa importante de lesão hepática aguda. As terapêuticas imunomoduladoras, como o vedolizumab (VDZ), são cada vez mais utilizadas para o tratamento de diversas patologias, particularmente a doença inflamatória do intestino. Vários estudos comprovaram o perfil de segurança favorável do VDZ. Até à data, apenas foi relatado um caso de hepatotoxicidade atribuída ao VDZ em estudos de farmacovigilância pós comercialização. Os autores apresentam o caso de uma mulher de 41 anos, seguida em Gastrenterologia por colite ulcerosa (CU) e hepatite autoimune (HAI). A doença hepática desta doente encontrava-se eficazmente controlada com corticoterapia em baixa dose (prednisolona 10 mg). Concomitantemente, a terapêutica dirigida à CU incluía salicilatos (messalazina 3 g/dia) e budesonido (9 mg/dia) orais. Por apresentar CU não controlada com o esquema referido, iniciou VDZ. Duas semanas após a primeira infusão de VDZ, a doente desenvolve manifestações clínicas e analíticas compatíveis com quadro de hepatite. Do estudo etiológico realizado, nenhuma causa foi identificada como responsável pela lesão hepatocelular. Foi realizada uma biópsia hepática que corroborou o diagnóstico de hepatite tóxica a sobrepor-se a características de doença hepática crónica. A terapêutica com VDZ foi interrompida e a doente apresentou recuperação de valores normais do perfil hepático durante as semanas que se sucederam. Com este trabalho, os autores expõem o primeiro caso pós-comercialização de lesão hepatocelular em provável relação com VDZ.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Vedolizumab]]></kwd>
<kwd lng="en"><![CDATA[Acute liver injury]]></kwd>
<kwd lng="en"><![CDATA[Hepatotoxicity]]></kwd>
<kwd lng="en"><![CDATA[Drug-induced liver injury]]></kwd>
<kwd lng="en"><![CDATA[Inflammatory bowel disease]]></kwd>
<kwd lng="pt"><![CDATA[Vedolizumab]]></kwd>
<kwd lng="pt"><![CDATA[Lesão hepática aguda]]></kwd>
<kwd lng="pt"><![CDATA[Hepatotoxicidade]]></kwd>
<kwd lng="pt"><![CDATA[Lesão hepática induzida por fármacos]]></kwd>
<kwd lng="pt"><![CDATA[Doença inflamatória intestinal]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aithal]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Björnsson]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplowitz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kullak-Ublick]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Larrey]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EASL Clinical Practice Guidelines: drug-induced liver injury]]></article-title>
<collab>European Association for the Study of the Liver</collab>
<collab>Clinical Practice Guideline Panel: Chair</collab>
<collab>Panel members</collab>
<collab>EASL Governing Board representative</collab>
<source><![CDATA[J Hepatol]]></source>
<year>2019</year>
<volume>70</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1222-61</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wendon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute liver failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>369</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>2525-34</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bergquist]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Broomé]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Lindgren]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wallerstedt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Almer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute liver failure in Sweden: etiology and outcome]]></article-title>
<source><![CDATA[J Intern Med]]></source>
<year>2007</year>
<volume>262</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>393-401</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bonovas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Doherty]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kucharzik]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Raine]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ECCO Guidelines on Therapeutics in Crohn&#8217;s Disease: medical Treatment]]></article-title>
<source><![CDATA[J Crohn&#8217;s Colitis]]></source>
<year>2020</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-22</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harbord]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Eliakim]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bettenworth]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Karmiris]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Katsanos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kopylov]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: current Management]]></article-title>
<collab>European Crohn&#8217;s and Colitis Organisation [ECCO]</collab>
<source><![CDATA[J Crohn&#8217;s Colitis]]></source>
<year>2017</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>769-84</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stine]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Behm]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic Cholestatic Liver Injury Attributable to Vedolizumab]]></article-title>
<source><![CDATA[J Clin Transl Hepatol]]></source>
<year>2016</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>277-80</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Benichou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries]]></article-title>
<source><![CDATA[J Clin Epidemiol]]></source>
<year>1993</year>
<volume>46</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1323-30</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colombel]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Sands]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Rutgeerts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Danese]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Haens]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The safety of vedolizumab for ulcerative colitis and Crohn&#8217;s disease]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2017</year>
<volume>66</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>839-51</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yajnik]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dubinsky]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Axler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abhyankar]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn&#8217;s Disease Patients Stratified by Age]]></article-title>
<source><![CDATA[Adv Ther]]></source>
<year>2017</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>542-59</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>The Medical Letter</collab>
<article-title xml:lang=""><![CDATA[Vedolizumab (Entyvio) for inflammatory bowel disease]]></article-title>
<source><![CDATA[Med Lett Drugs Ther]]></source>
<year>2014</year>
<volume>56</volume>
<numero>1451</numero>
<issue>1451</issue>
<page-range>86-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Bhayat]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Blake]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Travis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn&#8217;s Disease: 4 Years of Global Post-marketing Data]]></article-title>
<source><![CDATA[J Crohn&#8217;s Colitis]]></source>
<year>2020</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>192-204</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vermeire]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Colombel]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Feagan]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Sandborn]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sands]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Danese]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn&#8217;s disease: final results from the GEMINI LTS study]]></article-title>
<source><![CDATA[J Crohn&#8217;s Colitis]]></source>
<year>2019</year>
<volume>13</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S018-20</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
